What is the size of this protein in kDa?

This peptide was used to generate our c-Myc antibody NB600-336. This is just the c-Myc epitope tag so it's only about 1kDa. This peptide is intended to be a blocking peptide rather than for use in Western blot. 9E10 is also a commercial available antibody against the c-Myc tag, so this should work just fine.

What is the sequence?

Our sequence is considered proprietary, but we utilized a synthetic peptide made to the human c-Myc protein (between residues 400-450). Residues 400-450 contains the region used universally to c-Myc tag proteins.

Has this peptide been used as an absorption control for immunostaining with the c-myc antibody clone 9E10? What is the effective concentration of peptide per ml of optimally diluted antibody? Are there any punblications citing this procedure?

Our c-Myc peptide NB600-336PEP is a blocking peptide specific to our c-Myc antibody NB600-336. The NB600-336PEP peptide is a synthetic peptide made to the human c-Myc protein (between residues 400-450) [UniProt P01106]. We have tested this peptide in a western blot competition assay with our NB600-336 antibody. We used the peptide at a 50-200 molar excess of the antibody. This translates to approximately 5-10ug of peptide to every 1ug of antibody. Currently, we do not have any published reference using this peptide.

c-Myc Antibody Blocking Peptide

Name: c-Myc Antibody Blocking Peptide
Brand: Novus Biologicals
SKU: NB600-336PEP

Novus Biologicals, part of Bio-Techne | Catalog # NB600-336PEP

Submit a review

Product Datasheet / COA

100% Guarantee

Product Specifications
Preparation & Storage
Background
Product Documents
Specific Notices

Key Product Details

Conjugate

Unconjugated

Applications

Antibody Competition

View all c-Myc Proteins and Enzymes »

Product Specifications

Description

A MYC antibody blocking peptide.

Predicted Molecular Mass

48.8 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Application Notes

This peptide is useful as a blocking peptide for NB600-336. For further blocking peptide related protocol, click here.

Protein / Peptide Type

Antibody Blocking Peptide

Formulation, Preparation and Storage

NB600-336PEP

Formulation	dH2O
Concentration	1.0 mg/ml
Shipping	The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Store at -80C. Avoid freeze-thaw cycles.

Background: c-Myc

The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is a multifunctional, nuclear phosphoprotein that functions as a transcription factor with a theoretical molecular weight of 62kDa. However, c-Myc is extremely labile and is degraded very quickly even in extracts prepared with boiling SDS sample buffer, such that a molecular weight of ~40 kDa has been observed. c-Myc is part of a heterodimeric complex with Max that acts as a potent transcriptional activator. c-Myc is modified by glycosylation and phosphorylation and has been shown to interact with numerous proteins including SMAD2, SMAD3, LSD1/KDM1A, MAD, and Sp1 (1).

A basic Helix-Loop-Helix, Leucine Zipper domain (bHLH/LZ), designated Max, specifically associates with c-Myc, N-Myc and L-Myc proteins. The Myc-Max complex binds to DNA in a sequence-specific manner under conditions where neither Max nor Myc exhibit appreciable binding. Max can also form heterodimers with other bHLH-Zip proteins, Mad and Mxi1. c-Myc plays a role in cell cycle progression, apoptosis, cellular transformation and angiogenesis (2). Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of cancers including B-cell Lymphomas, acute myeloid leukemia, glioblastoma, stomach adenocarcinoma, and prostate adenocarcinoma (3).

References

1. Wilkinson, D. S., Tsai, W. W., Schumacher, M. A., & Barton, M. C. (2008). Chromatin-bound p53 anchors activated Smads and the mSin3A corepressor to confer transforming-growth-factor-beta-mediated transcription repression. Mol Cell Biol, 28(6), 1988-1998. doi:10.1128/mcb.01442-07

2. Pedrosa, A. R., Bodrug, N., Gomez-Escudero, J., Carter, E. P., Reynolds, L. E., Georgiou, P. N., . . . Hodivala-Dilke, K. M. (2019). Tumor Angiogenesis Is Differentially Regulated by Phosphorylation of Endothelial Cell Focal Adhesion Kinase Tyrosines-397 and -861. Cancer Res, 79(17), 4371-4386. doi:10.1158/0008-5472.Can-18-3934

3. Nagasaka, M., Tsuzuki, K., Ozeki, Y., Tokugawa, M., Ohoka, N., Inoue, Y., & Hayashi, H. (2019). Lysine-Specific Demethylase 1 (LSD1/KDM1A) Is a Novel Target Gene of c-Myc. Biol Pharm Bull, 42(3), 481-488. doi:10.1248/bpb.b18-00892

Long Name

v-Myc Avian Myelocytomatosis Viral Oncogene Homolog (Avian)

Alternate Names

cMyc, Myc, Myc2, Niard, Nird

Gene Symbol

MYC

Additional c-Myc Products

Product Documents for c-Myc Antibody Blocking Peptide

Product Datasheets

Download Product Datasheets

COA

Product Specific Notices for c-Myc Antibody Blocking Peptide

This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.

Citations
Reviews